17288-15-2

Basic information

• Product Name: Ethyl 2-amino-2-methylpropanoate hydrochloride
• Synonyms: H-AIB-OET HCL;H-AIB-OET HYDROCHLORIDE;H-ALPHA-ME-ALA-OET HCL;IFLAB-BB F2108-0015;2-AMINOISOBUTYRIC ACID ETHYL ESTER HYDROCHLORIDE;ALPHA-AMINOISOBUTYRIC ACID ETHYL ESTER HYDROCHLORIDE;2-Aminoisobutyric acid ethyl ester hydrochloride, 2-Methylalanine ethyl ester hydrochloride, alpha-Amino-2-methylbutyric acid ethyl ester hydrochloride, 2,2-Dimethylglycine ethylester hydrochloride;2-Amino-2-methyl-propionic acid ethyl ester hydrochloride
• CAS NO: 17288-15-2
• Molecular Formula: C₆H₁₄NO₂*Cl
• Molecular Weight: 167.63
• EINECS: 1533716-785-6
• Product Categories: Amino Acids & Derivatives;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate
• Mol File: 17288-15-2.mol

Chemical Properties

• Melting Point: 156-157 °C
• Boiling Point: 191.4 °C at 760 mmHg
• Flash Point: 69.5 °C
• Appearance: /
• Vapor Pressure: 0.438mmHg at 25°C
• Storage Temp.: Store at 0-5°C
• CAS DataBase Reference: Ethyl 2-amino-2-methylpropanoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-amino-2-methylpropanoate hydrochloride(17288-15-2)
• EPA Substance Registry System: Ethyl 2-amino-2-methylpropanoate hydrochloride(17288-15-2)

Safety Data

• Hazardous Substances Data: 17288-15-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-amino-2-methylpropanoate hydrochloride is used as an amino acid derivative for its potential role in pharmaceutical compositions. As an amino acid derivative, it can be utilized in the development of new drugs or formulations that target specific medical conditions or diseases. Its unique structure and properties make it a promising candidate for various pharmaceutical applications, including the treatment of certain illnesses or the enhancement of drug delivery systems.

InChI:InChI=1/C6H13NO2.ClH/c1-4-9-5(8)6(2,3)7;/h4,7H2,1-3H3;1H

Upstream product

• 62-57-7 2-Aminoisobutyric acid 
• 84758-56-5 ethyl 2-((tert-butoxycarbonyl)amino)-2-methylpropanoate 
• 64-17-5 ethanol 
• 15028-41-8 methyl 2-aminoisobutyrate hydrochloride 

Downstream Products

• 77919-05-2 2-Benzoylamino-2-methyl-propionsaeureaethylester 
• 172150-79-7 ethyl 2-(5-phenylthiazolidin-4-on-3-yl)isobutyrate 
• 875056-38-5 2-chloro-4-(4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)benzonitrile 

Relevant articles and documents

Microwave-Assisted Ruthenium- and Rhodium-Catalyzed Couplings of α-Amino Acid Ester-Derived Phosphinamides with Alkynes

Two different types of new phosphinamide α-amino ester derivatives have been prepared in moderate to high yields via ruthenium(II) and rhodium(III)-catalyzed ortho-C?H functionalization under microwave irradiation. Specifically, the ortho-alkenylated phosphinamides were produced through coupling of phosphinamides containing an α-substituted or α,α-disubstituted α-amino ester with internal alkynes under ruthenium catalysis. In contrast, Ru and the more effective Rh-catalyzed coupling of the α-unsubstituted glycine ester phosphinamide with alkynes resulted in formation of oxidative annulation products, phosphaisoquinolin-1-ones. The developed methods feature the use of easily accessible starting materials, short reaction time, exclusive E-stereoselectivity (for ortho-alkenylation) and good functional group tolerance. The alkenylation reaction was readily scaled up to gram scale. Furthermore, the obtained alkenylated phosphinamide could be transformed into P-containing dipeptides through hydrolysis of the ester group in the catalysis product and subsequent condensation with an α-amino ester.

ANTIVIRAL PRODRUGS OF TENOFOVIR

Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS

Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.

New Amino-Acid-Based β-Phosphorylated Nitroxides for Probing Acidic pH in Biological Systems by EPR Spectroscopy

There is increasing interest in measuring pH in biological samples by using nitroxides with pH-dependent electron paramagnetic resonance (EPR) spectra. Aiming to improve the spectral sensitivity (ΔaX) of these probes (i.e., the difference between the EPR hyperfine splitting (hfs) in their protonated and unprotonated forms), we characterized a series of novel linear α-carboxy, α′-diethoxyphosphoryl nitroxides constructed on an amino acid core and featuring an (α or α′)-C?H bond. In buffer, the three main hfs (aN, aH, and aP) of their EPR spectra vary reversibly with pH and, from aP or aH titration curves, a two- to fourfold increase in sensitivity was achieved compared to reference imidazoline or imidazolidine nitroxides. The crystallized carboxylate 10 b (pKa ≈3.6), which demonstrated low cytotoxicity and good resistance to bioreduction, was applied to probe stomach acidity in rats. The results pave the way to a novel generation of highly sensitive EPR pH markers.

METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS

Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae vims infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula (IV): The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.

PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF

The present invention relates to a novel process for producing anagrelide, 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin 2(3H)-one, or certain analogues thereof. The process of the invention also provides improved processes for producing key intermedia

PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF

The present invention relates to a novel process for producing anagrelide, 6,7-dichloro-1,5- dihydroimidazo [2,1-b] quinazolin 2 (3H)-one, or certain analogues thereof. The process of the invention also provides improved processes for producing key interm

Antiviral phosphoramidates

The invention provides novel nucleoside compounds of formula I wherein R1, R2a, R2b, R3, R4, R5, R6, R8a, R9 and R10 are as defined herein which are useful for the treatment of Hepatitis C Virus (HCV) mediated diseases. The invention further provides methods for treatment or prophylaxis of HCV mediated diseases with compounds of formula I and pharmaceutical compositions comprising these compounds,

Microwave-assisted, zinc-mediated peptide coupling of N-benzyl-α,α-disubstituted amino acids

Incorporation of the extremely hindered amino acid N-benzylaminoisobutyric acid into dipeptides under microwave irradiation with commercial zinc dust is described. A comparative survey of various methodologies for hindered peptide couplings was undertaken

CHEMICAL COMPOUNDS

Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The phosphoramidate moiety has attached to the P atom an aryl-O moiety and an α-amino acid moiety. The α-amino acid moiety may correspond to or be derived from either a naturally occurring or a non-naturally occurring amino acid.